AKT1 and breast carcinoma: Furthermore, CAFs that express specific proteins are also involved in tumor resistance to targeted therapy, such as CAFs expressing high-level Neuregulin 1 (NRG1) can lead to trastuzumab resistance in HER-2+ breast cancer through the HER3/AKT pathway [107].